<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397241</url>
  </required_header>
  <id_info>
    <org_study_id>A733</org_study_id>
    <nct_id>NCT00397241</nct_id>
  </id_info>
  <brief_title>24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations</brief_title>
  <official_title>24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this crossover trial is to compare the 3-month mean 24-hour&#xD;
      intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC)&#xD;
      given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening&#xD;
      and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and&#xD;
      latanoprost 0.005% given once in the evening in open-angle glaucoma patients who are&#xD;
      insufficiently controlled with latanoprost monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour IOP control with DTFC will be statistically similar with LTFC given once each evening and placebo in the morning.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjunctive therapy with DTFC and latanoprost will provide significantly better 24-hour IOP control than both fixed combinations alone (DTFC and LTFC).</measure>
  </primary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: dorzolamide/timolol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: latanoprost/timolol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide/timolol and latanoprost</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (artificial tears)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive primary open-angle (POAG) and exfoliative glaucoma (XFG) patients will be&#xD;
             recruited.&#xD;
&#xD;
          -  Patients included will be older than 29 years&#xD;
&#xD;
          -  Have early to moderate POAG, or XFG (less than 12 mean deviation visual field loss&#xD;
             attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio)&#xD;
&#xD;
          -  Will be on therapy with latanoprost for more than 3 months;&#xD;
&#xD;
          -  Have at treated baseline IOP at 10:00 (two consecutive readings) greater than 21 mm Hg&#xD;
&#xD;
          -  Have a reliable visual field (at least two visual fields with less than 30% fixation&#xD;
             losses, false positives or negatives)&#xD;
&#xD;
          -  Have a best corrected distance Snellen visual acuity &gt; 1/10&#xD;
&#xD;
          -  Have corneal pachymetry within the 550 ± 55 μm range, understand the study&#xD;
             instructions and are willing to attend all follow-up appointments&#xD;
&#xD;
          -  Are willing to comply with study medication usage&#xD;
&#xD;
          -  And have open, normal appearing angles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if they have: a risk for significant deterioration during&#xD;
             the study&#xD;
&#xD;
          -  Known previous history of lack of adequate response (&lt; 10% reduction) to any topical&#xD;
             glaucoma medication&#xD;
&#xD;
          -  Less than 20% daytime IOP reduction on latanoprost;&#xD;
&#xD;
          -  Systemic contraindications to topical beta-blockers (asthma, bradycardia, severe&#xD;
             congestive heart disease)&#xD;
&#xD;
          -  Known contraindications to prostaglandins, history of ocular herpetic disease, or&#xD;
             cystoid macular edema&#xD;
&#xD;
          -  History of trauma, inflammation, surgery or past use of steroids (within two months)&#xD;
&#xD;
          -  Severe dry eyes&#xD;
&#xD;
          -  Use of contact lenses&#xD;
&#xD;
          -  Signs of ocular infection, except blepharitis&#xD;
&#xD;
          -  Corneal abnormality that may affect IOP measurements&#xD;
&#xD;
          -  Unwillingness to accept the risk for hyperchromia of the iris or development of&#xD;
             hypertrichosis&#xD;
&#xD;
          -  And females of childbearing potential or lactating mothers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios GP Konstas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Unit, A University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Unit, A University Dept of Ophthalmology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 43</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 6, 2006</study_first_submitted>
  <study_first_submitted_qc>November 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2006</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

